Reach Us +19473334405
Patent Protection Of Monoclonal Antibodies Useful To Combat Multidrug-resistant Bacteria | 104958
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Patent protection of monoclonal antibodies useful to combat multidrug-resistant bacteria

Joint Event on 22nd Global Congress on Biotechnology & 5th International Conference on Enzymology and Protein Chemistry

Katia dos Reis, Jose Procopio Moreno Senna and Gisele Rodrigues Atayde

Institute of Immunobiological Technology, BrazilUniversity of Sao Paulo at Sao Carlos School of Engineering, Brazil

Posters & Accepted Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X-C2-116

Over the past 10 years, there has been an increasing demand for biopharmaceuticals, especially monoclonal antibodies. The rate of these biological products was significantly higher than the rate of traditional pharmaceuticals. Biopharmaceuticals now account for more than 15% of the total market and there is a forecast that sales of biopharmaceuticals should exceed $250,000,000,000 by 2020. The growth in demand of these products can be justified by the high specificity of monoclonal antibodies and the need for researchers and the market to develop new products, new technologies that could be used to combat various diseases. Multidrug-resistant bacteria strains are a global problem and the use of monoclonal antibodies to combat hospital infections may be a valuable alternative to public health. Another important aspect is the patent protection of these new assets, especially in the Institute of Immunobiological Technology (Bio-Manguinhos), a unit of the Oswaldo Cruz Foundation (Fiocruz) responsible for research, innovation, technological development and production of vaccines, rapid test devices and biopharmaceuticals aimed at meeting the demands of national public health.

Katia dos Reis completed her Bachelor of Chemistry and Master of Biochemistry at the Federal University of Rio de Janeiro. She is a Professor of Chemistry in the State Department of Rio de Janeiro and did her PhD Graduate Program in Technology of Chemical and Biochemical Processes of the School of Chemistry at the Federal University of Rio de Janeiro. Currently, she has been a Patent Analyst at the Bio-Manguinhos Technological Transfer Office (TTO-BIO), advising researchers on the protection of products and processes from Bio-Manguinhos/Fiocruz Technological Development.

E-mail: [email protected]